tetano
Editor, Senior Moderator
PLoS One
. 2022 Nov 9;17(11):e0276781.
doi: 10.1371/journal.pone.0276781. eCollection 2022.
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank
Holly Pavey[SUP] 1 [/SUP], Spoorthy Kulkarni[SUP] 2 [/SUP], Angela Wood[SUP] 3 4 5 6 7 [/SUP], Yoav Ben-Shlomo[SUP] 8 [/SUP], Peter Sever[SUP] 9 [/SUP], Carmel McEniery[SUP] 1 [/SUP], Ian Wilkinson[SUP] 1 [/SUP]
Affiliations
Abstract
Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of anti-hypertensive medication is related to this risk. Analyses were conducted using data from the UK Biobank and linked health records. Logistic regression models were fitted to assess the impact of hypertension, systolic blood pressure (SBP) and medications on the risk of severe COVID-19. 16,134 individuals tested positive for severe acute respiratory syndrome-coronavirus, 22% (n = 3,584) developed severe COVID-19 and 40% (n = 6,517) were hypertensive. Hypertension was associated with 22% higher odds of severe COVID-19 (Odds ratio (OR) 1.22; 95% confidence interval (CI) 1.12, 1.33), compared with normotension after adjusting for confounding variables. In those taking anti-hypertensive medications, elevated SBP showed a dose-response relationship with severe COVID-19 (150-159mmHg versus 120-129mmHg (OR 1.91; 95% CI 1.44, 2.53), >180+mmHg versus 120-129mmHg (OR 1.93; 95% CI 1.06, 3.51)). SBP <120mmHg was associated with greater odds of severe COVID-19 (OR 1.40; 95% CI 1.11, 1.78). Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers were not associated with altered risk of severe COVID-19. Hypertension is an important risk factor for COVID-19. A better understanding of the underlying mechanisms is warranted in case of more severe strains or other viruses in the future.
. 2022 Nov 9;17(11):e0276781.
doi: 10.1371/journal.pone.0276781. eCollection 2022.
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank
Holly Pavey[SUP] 1 [/SUP], Spoorthy Kulkarni[SUP] 2 [/SUP], Angela Wood[SUP] 3 4 5 6 7 [/SUP], Yoav Ben-Shlomo[SUP] 8 [/SUP], Peter Sever[SUP] 9 [/SUP], Carmel McEniery[SUP] 1 [/SUP], Ian Wilkinson[SUP] 1 [/SUP]
Affiliations
- PMID: 36350810
- DOI: 10.1371/journal.pone.0276781
Abstract
Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of anti-hypertensive medication is related to this risk. Analyses were conducted using data from the UK Biobank and linked health records. Logistic regression models were fitted to assess the impact of hypertension, systolic blood pressure (SBP) and medications on the risk of severe COVID-19. 16,134 individuals tested positive for severe acute respiratory syndrome-coronavirus, 22% (n = 3,584) developed severe COVID-19 and 40% (n = 6,517) were hypertensive. Hypertension was associated with 22% higher odds of severe COVID-19 (Odds ratio (OR) 1.22; 95% confidence interval (CI) 1.12, 1.33), compared with normotension after adjusting for confounding variables. In those taking anti-hypertensive medications, elevated SBP showed a dose-response relationship with severe COVID-19 (150-159mmHg versus 120-129mmHg (OR 1.91; 95% CI 1.44, 2.53), >180+mmHg versus 120-129mmHg (OR 1.93; 95% CI 1.06, 3.51)). SBP <120mmHg was associated with greater odds of severe COVID-19 (OR 1.40; 95% CI 1.11, 1.78). Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers were not associated with altered risk of severe COVID-19. Hypertension is an important risk factor for COVID-19. A better understanding of the underlying mechanisms is warranted in case of more severe strains or other viruses in the future.